Dr. Timothy Miller Wins $50,000 Sheila Essey Award for ALS Research
Washington, D.C., (March 7, 2018) — The ALS Association, in partnership with the American Academy of Neurology (AAN), and the American Brain Foundation, are awarding the 2018 Sheila Essey Award for ALS Research to Timothy M. Miller, M.D., Ph.D., the David Clayson Professor of Neurology from the Washington University School of Medicine in St. Louis. The award recognizes significant research contributions in the search for the causes, prevention, and cure for amyotrophic lateral sclerosis (ALS). Since 1996, The ALS Association and the American Academy of Neurology have jointly chosen recipients of the award.
Click here to read the full press release.
Phase 1 Clinical Trial to Test BIIB067 in People with ALS Currently Recruiting Participants – Muscular Dystrophy Association
In this article, the MDA announces the initiation of enrollment in the Phase I/II trial of SOD1 antisense oligonucleotides. Dr. Timothy Miller led the first trial of these SOD1 ASOs in ALS patients and is now the academic Principle Investigator for the Phase I/II trial, sponsored by Biogen Idec and Ionis Pharmaceuticals.
Medical Research Roundup – St. Louis Post-Dispatch
The St. Louis Post-Dispatch recently recognized Dr. Tim Miller’s newly awarded $2.3 million research grant from the National Institutes of Health. “The Miller Lab has found differences between healthy people and people with amyotrophic lateral sclerosis (ALS) in biomolecules known as microRNAs. This project seeks to understand the microRNA differences and the effect of adjusting them to try to develop new diagnostic tests or treatments for ALS.”
Genetic Mutations Linked to Higher Proportion of ALS Cases Than Previously Believed – ALSnewstoday.com
This news feature describes a new publication by Dr. Miller and other colleagues. Their research indicates that genetic mutations may underlie more ALS cases than scientists originally thought. Dr. Miller’s close colleague Dr. Matthew Harms states, “To our surprise, we found that 26 percent of sporadic ALS patients had potential mutations in one of the known ALS genes we analyzed. This suggests that mutations may be contributing to significantly more ALS cases.”
ALS trial shows novel therapy is safe – Futurity.org
An article from futurity.org highlights the exciting new results from Dr. Miller’s first Phase I trial of SOD1-targeting ASOs, stating that the investigational treatment for inherited forms of ALS has passed an early clinical trial for safety. “These results let us move forward in the development of this treatment and also suggest that it’s time to think about applying this same approach to other mutated genes that cause central nervous system disorders,” says lead author Timothy Miller, assistant professor of neurology at Washington University in St. Louis.
Breakthrough ALS Research at Washington University – Fox2Now St. Louis
Dr. Miller is featured in this news article and video about his Phase I clinical trial of antisense oligonucleotides targeting the SOD1 protein in ALS patients with SOD1 mutations. “We can do go in a technique called antisense oligo nucleotides and take that small mistake in those RNA instructions and like a small eraser and go in an erase that mistake and fix it.” said Dr. Timothy Miller.